Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03296059|
Recruitment Status : Recruiting
First Posted : September 28, 2017
Last Update Posted : March 27, 2018
Acute respiratory distress syndrome (ARDS) in neonates has been defined in 2017.
The death rate is over 50%.There are no special treatments for acute respiratory distress syndrome.
|Condition or disease||Intervention/treatment||Phase|
|Red Blood Cells(RBC) Acute Respiratory Distress Syndrome (ARDS)||Other: conventional treatment with RBC transfusion Other: conventional treatment||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates: A Randomized Controlled Trial|
|Actual Study Start Date :||October 1, 2017|
|Estimated Primary Completion Date :||October 1, 2020|
|Estimated Study Completion Date :||October 1, 2020|
Experimental: RBC transfusion with conventional treatment
Besides conventional treatment,neonates diagnosed with ARDS is treated with RBC transfusion.
Other: conventional treatment with RBC transfusion
Besides conventional treatment, neonates is given RBC transfusion.
Active Comparator: conventional treatment
neonates diagnosed with ARDS is treated with conventional treatment.
Other: conventional treatment
neonates is treated with conventional treatment.
- death rate [ Time Frame: within 100 days ]neonate died due to respiratory failure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03296059
|Contact: Ma Juan, MDemail@example.com|
|Contact: Ma Juan, MDfirstname.lastname@example.org|
|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||Recruiting|
|Chongqing, Chongqing, China, 400042|
|Contact: Shi Yuan, PhD,MD|
|Principal Investigator:||Shi Yuan, PhD,MD||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|